Federal Trade Commission Actions on Prescription Drugs, 2000-2022

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 20, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.5737?guestAccessKey=b5df0e55-79b2-4af8-9a64-87a6674156de&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052024

 

About The Study: The Federal Trade Commission (FTC) brought about one enforcement action and three merger actions per year against pharmaceutical manufacturers from 2000-2022, pursuing a small fraction of the estimated misconduct and consolidation in the pharmaceutical marketplace. Although the FTC faces substantial legal and practical limitations, important tools remain untested, including a rule defining “unfair methods of competition,” that may allow it to more effectively prevent repetitive patterns of anticompetitive behavior. 

Corresponding Author: To contact the corresponding author, Aaron S. Kesselheim, M.D., J.D., M.P.H., email akesselheim@bwh.harvard.edu.

 

(doi:10.1001/jama.2024.5737)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.